568
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma

ORCID Icon, , , , , , , & ORCID Icon show all
Pages 1325-1334 | Received 04 Jan 2021, Accepted 06 Apr 2021, Published online: 08 May 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Patrick Squires, Justin Puckett, Katherine Elizabeth Ryland, Sachin Kamal-Bahl, Monika Raut, Jalpa A. Doshi & Scott F. Huntington. (2023) Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs. Leukemia & Lymphoma 64:11, pages 1752-1770.
Read now

Articles from other publishers (2)

Lisa M. Hess, Yongmei Chen, Paolo B. Abada, Heiko Konig & Richard A. Walgren. (2022) Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study. Advances in Hematology 2022, pages 1-8.
Crossref
Shinya Rai, Yoshinori Tanizawa, Zhihong Cai, Yu-Jing Huang, Kaisa Taipale & Masaomi Tajimi. (2022) Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. Advances in Therapy 39:10, pages 4792-4807.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.